#oncology #immunotherapy #AkariTherapeutics #novelPH1payload #targetedcancertherapy #PH1 #antibodydrugconjugates #ADCs #oncogenicmutations #DNAsplicing #neoantigens #missplicedproteins #effluxtransporters #oncogenicdrivers #PH1spliceosomemodulatorpayload
pharmatimes.com/news/akari-t...
pharmatimes.com/news/akari-t...
Akari Therapeutics advances research on novel PH1 payload for targeted cancer therapy - PharmaTimes
Akari Therapeutics has reaffirmed its commitment to advancing research on PH1, a novel spliceosome modulator payload used in its antibody drug conjugates
pharmatimes.com
August 11, 2025 at 9:09 AM
New research shows that #CellCycle length influences whether a #mutation causes #cancer or remains harmless, with implications for developing treatments that boost the body's natural #CancerDefenses.
#CancerMechanisms #OncogenicMutations
#CancerMechanisms #OncogenicMutations
Why some cells are more susceptible to cancer – BioNews Central
New research shows that cell cycle length influences whether a mutation causes cancer or remains harmless, with implications for developing treatments that boost the body's natural cancer defenses. ...
sbee.link
May 1, 2025 at 2:49 PM
New research shows that #CellCycle length influences whether a #mutation causes #cancer or remains harmless, with implications for developing treatments that boost the body's natural #CancerDefenses.
#CancerMechanisms #OncogenicMutations
#CancerMechanisms #OncogenicMutations